Baxter anticipates launching seven to nine new products annually over the next few years, increasing to 10 to 15 anticipated new product launches a year beyond 2019.
State senators voted 22-9 in favor of approving a measure intended to help ease the state’s growing opioid epidemic.
Mometasone furoate, available in 50 mcg/spray strength, is an AB-rated therapeutic equivalent to Nasonex.
Alembic Pharmaceuticals’ Fluoxetine Hydrochloride tablets are used for the treatment of depression and panic disorder.
Multiple news outlets state company could receive $2 billion in proceeds for the company it acquired from Merck KGaA’s Merck Serono in 2010.
Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg is indicated for the treatment of major depressive disorder and prevention of seasonal affective disorder in adults.
Specialty pharmaceutical company could be acquired by Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA.
Abacavir and Lamivudine Tablets USP, 600 mg/300 mg, are AB-rated generic equivalents to the reference listed drug, Epzicom Tablets, 600 mg/300 mg of ViiV Healthcare.
Rivelsa is an estrogen/progestin COC intended for use by women to prevent pregnancy.
Abacavir Sulfate and Lamivudine Tablets, 600 mg/300 mg to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Epzicom Tablets of ViiV Healthcare.